PHAT

5.99

5.52% -0.35

Handel nachbörslich: 5.99

Phathom Pharmaceuticals Inc (PHAT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.34

Offen:

$6.31

24-Stunden-Volumen:

1.44M

Relative Volume:

1.14

Marktkapitalisierung:

$409.58M

Einnahmen:

Nettoeinkommen (Verlust:

$-297.11M

KGV:

-1.1541

EPS:

-5.19

Netto-Cashflow:

$-216.95M

1W Leistung:

-13.19%

1M Leistung:

-26.23%

6M Leistung:

-49.32%

1J Leistung:

-10.60%

1-Tages-Spanne:

$5.945

$6.33

1-Wochen-Bereich:

$5.945

$7.01

52-Wochen-Spanne:

$5.945

$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Firmenname

Phathom Pharmaceuticals Inc

Sektor

Healthcare (1173)

Branche

Biotechnology (678)

Telefon

(877) 742-8466

Adresse

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Mitarbeiter

112

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PHAT's Discussions on Twitter

Vergleichen Sie PHAT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PHAT Phathom Pharmaceuticals Inc	5.99	409.58M	0	-297.11M	-216.95M	-5.19
VRTX Vertex Pharmaceuticals Inc	461.68	118.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	672.98	73.95B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	655.13	39.81B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	271.31	34.99B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	123.77	29.67B	3.30B	-501.07M	1.03B	-2.1146

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-03	Eingeleitet	Stifel	Buy
2024-01-05	Bestätigt	Needham	Buy
2023-08-09	Eingeleitet	H.C. Wainwright	Buy
2023-05-11	Hochstufung	Evercore ISI	In-line → Outperform
2023-03-13	Eingeleitet	Craig Hallum	Buy
2022-10-21	Eingeleitet	Jefferies	Buy
2022-05-06	Herabstufung	Evercore ISI	Outperform → In-line
2021-05-12	Hochstufung	Goldman	Sell → Neutral
2021-02-17	Eingeleitet	BMO Capital Markets	Outperform
2021-02-02	Eingeleitet	Guggenheim	Buy
2020-06-26	Herabstufung	Goldman	Neutral → Sell
2019-11-20	Eingeleitet	Evercore ISI	Outperform
2019-11-19	Eingeleitet	Goldman	Neutral
2019-11-19	Eingeleitet	Jefferies	Buy
2019-11-19	Eingeleitet	Needham	Buy

Alle ansehen

Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten

Jan 31, 2025

Further weakness as Phathom Pharmaceuticals (NASDAQ:PHAT) drops 12% this week, taking five-year losses to 81% - Simply Wall St

Jan 31, 2025

Jan 29, 2025

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Jan 29, 2025

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.

Jan 29, 2025

Jan 27, 2025

Trading (PHAT) With Integrated Risk Controls - Stock Traders Daily

Jan 27, 2025

Jan 26, 2025

Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN

Jan 26, 2025

Phathom Pharmaceuticals Stock: A Comprehensive Analysis of Recent Developments - The Digital Weekly

Jan 26, 2025

Jan 24, 2025

Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells 7,886 Shares of Stock - MarketBeat

Jan 24, 2025

Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 6,583 Shares of Stock - MarketBeat

Jan 24, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 Shares - MarketBeat

Jan 24, 2025

Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock By Investing.com - Investing.com South Africa

Jan 24, 2025

Jan 23, 2025

Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN

Jan 23, 2025

Jan 19, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Yahoo Finance

Jan 19, 2025

Jan 17, 2025

(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily

Jan 17, 2025

Jan 15, 2025

Barclays PLC Buys 45,402 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World

Jan 15, 2025

Jan 12, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World

Jan 12, 2025

Jan 10, 2025

Phathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Jan 10, 2025

Jan 06, 2025

(PHAT) Proactive Strategies - Stock Traders Daily

Jan 06, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Sold by Jane Street Group LLC - Defense World

Jan 06, 2025

Jan 02, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.9%Here's What Happened - MarketBeat

Jan 02, 2025

Dec 31, 2024

Barclays PLC Grows Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World

Dec 31, 2024

Dec 30, 2024

Geode Capital Management LLC Buys 56,871 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World

Dec 30, 2024

Dec 26, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 7.1% HigherWhat's Next? - MarketBeat

Dec 26, 2024

Dec 25, 2024

State Street Corp Raises Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World

Dec 25, 2024

State Street Corp Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat

Dec 25, 2024

Dec 20, 2024

Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock By Investing.com - Investing.com South Africa

Dec 20, 2024

Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock - Investing.com India

Dec 20, 2024

Phathom Pharmaceuticals COO sells shares for $8,944 - Investing.com India

Dec 20, 2024

Phathom Pharmaceuticals COO sells shares for $8,944 By Investing.com - Investing.com South Africa

Dec 20, 2024

Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of Stock - MarketBeat

Dec 20, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 2%Here's Why - MarketBeat

Dec 20, 2024